East Melbourne
East Melbourne
East Melbourne, Australia26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Infections, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, head and neck squamous cell carcinoma, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, polyomavirus infectious disease, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm, stomach disorder, triple-negative breast carcinoma, urinary system disorder, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07115043 | |
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06635148 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06143878 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants | Macular Telangiectasia Type 2 (MacTel) | Recruiting | Phase 4 | 2026-09-25 | NCT06971939 | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04557059 | |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Brain Metastases, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, histiocytosis, intestinal disorder, lung disorder, lung neoplasm, lymphatic system disorder, malignant endocrine neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor | Recruiting | Phase 1 / Phase 2 | 2026-09-16 | NCT05786924 | |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-09-08 | NCT05307705 | |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, autosomal dominant Parkinson disease 4, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-09-03 | NCT06989112 | |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 3 | 2026-08-28 | NCT07577856 | |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 3 | 2026-08-28 | NCT07577843 | |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT07681596 | |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT05367440 | |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-08-18 | NCT06792695 | |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-14 | NCT07764978 | |
| A Prospective Natural History Study in Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Active, not recruiting | Not stated | 2026-08-11 | NCT04588662 | |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) | Recruiting | Phase 1 / Phase 2 | 2026-08-06 | NCT06188520 | |
| A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-13 | NCT06112379 | |
| Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Nutritional and Metabolic Diseases, Optic Atrophy, Autosomal Dominant, cranial nerve neuropathy, eye disorder, hereditary disease, hereditary optic atrophy, inborn mitochondrial metabolism disorder, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, optic atrophy, optic nerve disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-29 | NCT06970106 | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-06-18 | NCT05221840 | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, adenocarcinoma, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, thyroid gland disorder, thyroid tumor | Recruiting | Phase 1 / Phase 2 | 2026-05-27 | NCT03093116 | |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-05-12 | NCT06879041 | |
| Natural History of PRPF31 Mutation-Associated Retinal Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, eye disorder, hereditary disease, inherited retinal dystrophy, retinal degeneration, retinal disorder, retinitis pigmentosa | Active, not recruiting | Not stated | 2026-04-13 | NCT05573984 | |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-23 | NCT06267729 | |
| A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2025-07-31 | NCT05061134 |